CN104168772A - Food composition comprising vitamin k and saturated fat and its use - Google Patents

Food composition comprising vitamin k and saturated fat and its use Download PDF

Info

Publication number
CN104168772A
CN104168772A CN201380014323.XA CN201380014323A CN104168772A CN 104168772 A CN104168772 A CN 104168772A CN 201380014323 A CN201380014323 A CN 201380014323A CN 104168772 A CN104168772 A CN 104168772A
Authority
CN
China
Prior art keywords
composition
vitamin
blood
fat
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380014323.XA
Other languages
Chinese (zh)
Inventor
雷娜特·马里·路易斯·兹维伊森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FrieslandCampina Nederland BV
Original Assignee
Friesland Brands BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friesland Brands BV filed Critical Friesland Brands BV
Publication of CN104168772A publication Critical patent/CN104168772A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0056—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/001—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/1578—Calcium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/161—Magnesium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/714—Vitamin K
    • A23V2250/7144—Vitamin K2

Abstract

A food composition comprises fat and vitamin K, wherein the fat comprises at least 36% saturated fatty acids, and wherein the vitamin K is in the form MK-7 in an amount of at least 0.1 mcg MK-7 per daily intake. The composition preferably further comprises milk or milk derived ingredients, calcium, magnesium, potassium, polyunsaturated fatty acids and/or vitamin D. Preferably, the composition is a dairy composition such as a yogurt, milk drink, cheese, cream, etc.

Description

Food compositions that comprises vitamin K and saturated fat and uses thereof
The present invention relates to the food compositions that comprises vitamin K and saturated fat, and relate to especially the dairy compositions that is supplemented with vitamin K.The invention still further relates to the method for the preparation of said composition.In addition, the present invention relates to this food compositions for improving the bioavilability of vitamin K and active purposes.
Foreword
Vitamin K is one group of similar liposoluble vitamin of structure, and its posttranslational modification that is some protein is required, and for the metabolic pathway of blood clotting and bone and its hetero-organization required.They are 2-MNQ (3-) derivative.This group vitamin comprises two kinds of natural complex: vitamin K 1and vitamin K 2.
Vitamin K 1be also referred to as vitamin K j, phylloquinone or phytondione (being also referred to as plant naphthoquinones).Vitamin K 1required for blood coagulation, it is synthesized by plant, is present in green vegetable, and can be present in soybean oil.
Vitamin K 2participate in bone metabolism.Vitamin K 2homologue (menaquinone) is characterized by the number of the isoprenoid residue that comprises side chain.Menaquinone is abbreviated as MK-n, and wherein n represents the number of isoprenoid side chain.Therefore, MK-4 is abbreviated as in methylnaphthoquinone-4, and it has 4 isoprene residues in side chain.
The vitamin K of known three kinds of synthesis types: vitamin K 3, K 4and K 5.Although natural K 1and K 2form is nontoxic, but synthesized form K 3(menadione) illustrates toxicity.
Functional food is the emerging field in Food Science, and this is because it is more and more subject to the consumer's of unsoundness consciousness welcome.Functional food is any food or the food composition that the health benefits that surpasses traditional nutrients of wherein comprising can be provided.The general category of functional food comprises through processed food or with the food of sanatory reinforced by additive, for example, is rich in the product of vitamin.
Than the traditional food replenishers that comprise one or more of active components, thereby an advantage of functional food is that these active components are incorporated in conventional food product without separate administration, for example, with the form of vitamin supplement tablet.
Although the known much food with food supplement strengthening, for example, for providing the demand of functional food of specific health benefit (, cardiovascular health) still in continuous growth.
Yet the conventional food product that is supplemented with vitamin and/or mineral matter not always shows the expection health benefits based on added micronutrient.The micronutrient adding should be compatible with each other and with other component compatibility that are contained in food product.In addition, the interpolation of vitamin also can cause adverse effect to the organoleptic attribute of supplementary, for example, and taste, smell or denseness.In addition conventionally expect, good durability and the heat endurance of products obtained therefrom.
Current research result shows, small intestine and large intestine (colon) seem to absorb aspect vitamin K efficiency lower.These results are strengthened by cohort study, and wherein most of object illustrates the deficiency of vitamin K amount in body.This exist (indirectly testing to vitamin K deficiency) by a large amount of not exclusively gamma-carboxylation albumen in blood discloses.
Up to now, conventionally vitamin K is complemented in oil dispersion, wherein this oil is liquid vegetable oil.Think that vegetable oil reinforcement enteron aisle picked-up vitamin K enters blood, has biologically active thereby become in mammal.
Bruge etc. (Br J Nutr 106 (2011) 1-5 pages) are with being supplemented with the olive oil of MK-7, with the daily dose of 45 and 90 microgram MK-7, are studied.They find to only have 90 micrograms dose can produce biological effect.
Theuwissen etc. (Br J Nutr 107 (2012) 1-6 pages) have obtained similar data.They have studied in the fluid composition of natto oil (natto oil) and Linseed oil (linseed oil) intake of the MK-7 of 0,10,20,45,90,180 and 360 micro-grams/day.The discoveries such as Theuwissen, only, under high dose (90,180,360 micro-grams/day), its carboxylation on osteocalcin (osteocalcin) has remarkable impact.
Two researchs all find to only have the vitamin K (90 micrograms and higher/sky) of high dose that any remarkable impact to the carboxylation of osteocalcin and/or matrix Gla protein (Matrix Gla Protein, MGP) is shown.Van Summeren etc. (Br J Nutr 102 (2009) 1171-1178) have found in prepuberal children, the impact of the MK-7 of 45 micro-grams/day of dosage on osteocalcin carboxylation.It should be noted that this dosage be equivalent to be grown up 150 micro-grams/day (0.22 micromoles).
A kind of matrix is found in expectation, wherein can use with the described higher dosage vitamin K of prior art still equally effectively compared with low dosage vitamin K.Therefore, an object of the present invention is to provide the composition that is rich in vitamin K.Another object of the present invention is to improve the bioavilability of vitamin K.And another object of the present invention is to improve the biologically active of vitamin K.In addition, a further object of the present invention is maintain and/or support and/or improve vascular health, especially blood vessel elasticity (vascular flexibility) and/or blood flow.Another object of the present invention is prevention and/or stable metabolic syndrome and/or diabetes.And another object of the present invention is maintain and/or support and/or improve mental health.
Inventor's discovery, in blood, the bioavilability of vitamin K and stability depend on the type of used fatty type and vitamin K.Especially, than with how unsaturated liquid oil (for example sunflower oil, olive oil and/or Linseed oil) combined administration, farnoquinone (especially MK-7) and the vitamin K that there is the combination of the fat of 36wt% saturated fatty acid (for example, animal tallow and especially butter fat (butterfat) and/or butterfat (milk fat)) at least and cause higher concentration in blood.
Summary of the invention
In first aspect, the present invention relates to comprise the food compositions of fat and farnoquinone, wherein said fat comprises at least 36% saturated fatty acid, and wherein said farnoquinone is the MK-7 form of at least 0.1mcg MK-7/ daily intaking amount.In a preferred embodiment of the invention, this fat is selected from palm oil, palm olein, palm-kernel oil, shea nut (shea nut), mist ice grass grease (illipe), cottonseed oil, coconut oil, cocoa butter, butter fat, butterfat, lard, leaf fat (suet), tallow (tallow), its fraction, and any combination, and preferred animal tallow.In a preferred embodiment, described fat is butter fat, butterfat oil (butter oil), anhydrous milkfat (AMF), butterfat and/or its fraction.
In a preferred embodiment of the present invention and/or its some embodiments, described composition also comprises breast or from composition of milk.Preferably, the composition of the present invention and/or its some embodiments comprise be selected from the casein of casein, lactoalbumin, lactoglobulin, hydrolysis, the lactalbumin of hydrolysis, caseinate, lactose, curdled milk, milk powder, milk solids, butter solid, butterfat oil, lactic acid and/or recaldent from composition of milk.Should be understood that, in the present invention and/or its some embodiments, can predict the combination from composition of milk.
In another preferred embodiment of the present invention and/or its some embodiments, described composition comprises to be taken in 0.20 to 400mcg vitamin(e) M K-7/ day, more preferably, took in 0.5 to 400mcg/ day or every part (per serving).Suitably, according to the present invention and/or its some embodiments, said composition comprises the MK-7 within the scope of the absorption of 1 to 350mcg/ day, be more suitably to take in 2 to 300mcg/ days, more preferably 5 to 250mcg MK-7/ days were taken in, more preferably 10 to 200mcg MK-7/ days were taken in, more preferably 15 to 180mcg MK-7/ days were taken in, even more preferably 20 to 150mcg MK-7/ days were taken in, even more preferably 25 to 120mcg MK-7/ days were taken in, and more preferably took in 40 to 100mcg MK-7/ days and most preferably 50 to 90mcg MK-7/ days were taken in.Because vitamin K promotes blood clotting, it can not be supposed to, so the upper limit of MK-7 is preferably less than and takes in or every part 400mcg MK-7/ day in composition, and is more preferably less than 200mcg MK-7 and is most preferably less than and take in 100mcg MK-7/ day.
In another preferred embodiment of the present invention and/or its some embodiments, described composition also comprises the composition that is selected from the group that comprises calcium, magnesium, potassium, polyunsaturated fatty acid and vitamin D.The combination that should be understood that these compositions is possible.
In second aspect, the present invention relates to according to the present invention and/or the preparation method of the composition of its some embodiments, it comprises vitamin(e) M K-7 is added in the fatty composition of bag, wherein said fat contains at least saturated fatty acid of 36wt%.Optionally, the premix of vitamin(e) M K-7 is added in food product.Before premix is defined in and further uses during product preparation or mix, by two or more compositions or key element, mixed or the something of blend, it can suitably comprise other vitamins and mineral matter.Suitably, first MK-7 is mixed in fruit prepared product and/or fruit sugar syrups, is then added into and comprises in the fatty food product with 36wt% saturated fatty acid at least.
Another aspect of the present invention relates to according to the present invention and/or the composition of its some embodiments, and it is for supporting and/or maintaining and/or improve vascular health, particularly cardiovascular health.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintaining and/or improve blood vessel elasticity.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for prevention and/or maintain and/or alleviate artery sclerosis.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintaining and/or improve bone health.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintaining and/or improve normal blood coagulation ability and/or for maintaining orthoplastocyte cohesion and/or for preventing blood platelet to the adhesion of vascular wall and/or fatty spew (fatty plaque).
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintaining and/or improve glucose control and/or insulin secretion and/or insulin sensitivity.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for prevention and/or maintain and/or alleviate chronic inflammation and/or mild inflammation.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintaining and/or improve mental health and/or cognitive performance and/or vigilance and/or spiritual acuity (mental sharpness) and/or memory.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintain and/or improve the waistline of the body mass index (body mass index, BMI) of healthy body weight and/or health and/or the triglyceride blood level of health and/or health.The health status of all health parameters that the present invention mentions is preferably according to World Health Organization's guide (WHO guidelines for the prevention, management and care of diabetes melitus, 2006; Global strategy on diet, physical activity and health, WHO report, 2004).
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for maintaining healthy blood pressure and/or prevention and/or alleviating hypertension (according to WHO guide).
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintaining and/or improve blood flow.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it,, for supporting and/or maintaining and/or improve blood circulation, comprises systemic circulation (macrocirculation) and/or microcirculation.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for supporting and/or maintaining and/or improve hemoperfusion.This is the process that blood is delivered to the capillary bed of mammalian tissues (for example, to brain, kidney, heart, lung, liver, four limbs and stomach intestinal tissue).
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is for prevention and/or maintain and/or alleviate metabolic syndrome.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of vascular diseases and/or angiocardiopathy and/or atherosclerosis and/or artery sclerosis and/or hypertension and/or obstruction of artery and/or varication and/or TIA (transient ischemic attack, TIA) and/or palsy and/or cold limbs (cold limb).
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of blood vessel lack flexibility (vessel inflexibility).
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of bone demineralisation and/or osteoporosis.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of thrombosis and/or palsy.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of diabetes and/or insulin resistance.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of chronic inflammation and/or mild inflammation.
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of spirit go down (mental decline) and/or mental illness (for example dementia and/or Alzheimer disease).
The invention still further relates to according to the present invention and/or the composition of its some embodiments, it is used for the treatment of high triglyceride and/or high body weight and/or high waistline in obesity and/or metabolic syndrome and/or high BMI and/or blood.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintain and/or improve the purposes of vascular health and/or cardiovascular health.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintain and/or improve the purposes of blood vessel elasticity.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for prevention and/or maintain and/or alleviate arteriosclerotic purposes.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for maintaining the purposes of healthy blood pressure and/or prevention and/or alleviating hypertension (according to WHO guide).
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintain and/or improve the purposes of blood flow.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintaining and/or improve the blood circulation purposes of (comprising systemic circulation and/or microcirculation).
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting, maintain and/or improve the purposes of hemoperfusion.This is the process of the capillary bed of mammalian tissues (being for example delivered to brain, kidney, heart, lung, liver, four limbs and stomach intestinal tissue) that blood is delivered to.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintain and/or improve the purposes of bone health.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintaining and/or improve normal blood coagulation ability and/or maintain orthoplastocyte cohesion and/or the purposes of prevention blood platelet to the adhesion of vascular wall and/or fatty spew.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintain and/or improve the purposes of glucose controlling mechanism and/or insulin secretion and/or insulin sensitivity and/or prevention diabetes and/or hyperglycemia.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for prevention and/or maintain and/or alleviate chronic inflammation and/or subinflammatory purposes.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintain and/or improve the purposes of mental health and/or cognitive performance and/or vigilance and/or memory and/or spiritual acuity.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintaining and/or improve the purposes that healthy Weight management and/or healthy body mass index and/or healthy triglycerides blood level and/or prevention body fat weight increase.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for supporting and/or maintain healthy waistline and/or for reducing the purposes of high waistline.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for preventing and/or maintain and/or alleviate the purposes of metabolic syndrome.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for improving the purposes of the bioavilability of vitamin K and/or farnoquinone and/or MK-7.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for improving the bioactive purposes of vitamin K and/or farnoquinone and/or MK-7.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for improving the purposes of the level of mammalian vitamin K and/or farnoquinone and/or MK-7.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for reducing not carboxylation MGP and/or the not purposes of the cyclical level of carboxylation osteocalcin in mammalian.
The invention still further relates to according to the present invention and/or the composition of its some embodiments for improving the purposes of the cyclical level of mammalian carboxylation MGP and/or carboxylation osteocalcin.
In a preferred embodiment of the present invention and/or its some embodiments, in 12 weeks, preferably in 8 weeks, more preferably obtained in 4 weeks: not carboxylation MGP and/or the not reduction of the cyclical level of carboxylation osteocalcin in mammalian, and/or the rising of the cyclical level of carboxylation MGP and/or carboxylation osteocalcin, and/or the rising of the level of vitamin K and/or farnoquinone and/or MK-7 in mammalian.
The invention still further relates to by by according to the present invention and/or the composition of its some embodiments be applied to mammal and reduce not carboxylation MGP and/or the not method of the cyclical level of carboxylation osteocalcin in mammalian.
The invention still further relates to by by according to the present invention and/or the composition of its some embodiments be applied to the method that mammal is improved the cyclical level of carboxylation MGP in mammalian and/or carboxylation osteocalcin.
The invention still further relates to by by according to the present invention and/or the composition of its some embodiments be applied to the method that mammal is improved the level of farnoquinone in mammalian.
Preferably, according to the present invention and/or in the method for its some embodiments, by according to the present invention and/or the composition of its some embodiments use time at least 4 weeks, preferably at least 8 weeks, most preferably at least 12 weeks.Preferably, the composition of the present invention and/or its some embodiments is used throughout one's life, suitably, 3,5,7,10,12,15,18,20,23,25,27,30,32,35,38,40,45,50,55,60,65,70,75,80,85,90, or as many as 95 years even.The absorption of vitamin K and/or farnoquinone and/or MK-7 is preferably every day, every day, thereby keeps stable vitamin K, farnoquinone and/or MK-7 level in blood.Product of the present invention can be readily incorporated in normal health diet, make to improve every day, lifelong vitamin K, farnoquinone and/or MK-7 level.
Detailed Description Of The Invention
A kind of composition of the present composition is farnoquinone or methylnaphthoquinone.Farnoquinone is a member of vitamin K family, and wherein all members of this family have the naphthoquinones ring structure that methylates, and is connected to the aliphatic lateral chain difference at place, 3-position.Menaquinone has the side chain that the unsaturated isoprenoid residue by variable number forms; Conventionally by its called after MK-n, wherein n represents the number of isoprenoid.
Vitamin K family participates in the metabolism of blood clotting and calcium.Vitamin K sees in multivitamin fill-in and in infant formula conventionally.Yet it mainly exists with the form of phytomenadione, so in fact the general designation of vitamin K refer to phytomenadione because this form is quite cheap and for a long time since generally acknowledge that it is safe in food always.It should be noted that phytomenadione phylloquinone is different from farnoquinone methylnaphthoquinone.
Farnoquinone in the present invention is the form of MK-7, has the methylnaphthoquinone of the side chain consisting of 7 unsaturated isoprenoid residues.Should be understood that when mentioning vitamin K in this manual, mean farnoquinone, and be more particularly MK-7.Farnoquinone (for example MK-7) can be available from any suitable source, the soybean prod for example fermenting, for example natto.The farnoquinone of synthetic preparation is also suitable, and it has advantages of that the quality of the farnoquinone of such acquisition can be easy to control.Yet, can be preferably for example, available from the farnoquinone of natural origin (, passing through microorganisms).Cheese comprises natively and has the farnoquinone of growing (being generally MK-8, MK-9 and longer) isoprenoid chain.
In this manual, with daily intake or every deal or every product weight amount or volume, the content of MK-7 in the present composition and other compositions is characterized.Conventionally with every feed ration, represent the amount of vitamin.Label for food product, many national legislations show as recommending daily intake (recommended daily intake, RDI) or recommend a day quantity delivered (recommended daily allowance, RDA) vitamin amount, electronics compilation (http://www.ecfr.gov/cgi-bin/text-idx referring to for example federal regulations 21 § 101 chapters? c=ecfr & sid=8c5344f04a8ae103e5b0ff5a17c7fa97 & rgn=div8 & view=te xt & node=21:2.0.1.1.2.4.1.1 & idno=21).In Europe, according to the indication 90/496/EEC that is devoted to nutrients label requirement, the information table about vitamin and mineral matter must be shown and recommend day percentage of quantity delivered (RDA).For the present invention, scale is shown to microgram (mcg), nanogram (ng), milligram (mg) or gram (g).For viscosity (can spoon with) product, portion is about 125 grams, or for example, is approximately 200 to 250ml for pourable products (, breast or yogurt drink).For cheese, portion means a section of approximately 20 to 40g, and is approximately 3.5 to 7 grams for conventionally a for the smear using together with a section of bread or butter.Day is taken in and means every day along with the total amount of the composition of the product internal consumption of product of the present invention.Take in day and can aly consume, but also can be divided into over 2,3,4 parts or even more parts/days.Take in day and also can spread all over several prods, such as breast and yogurt, breast and cheese etc.The suitable consumption that technical staff can the information based on provided finds part, or product is appropriately combined.For example, can use and drink the be generally once or twice/sky of consumption of type yogurt by spoon, so take in normally one to two part of/day day.For cheese, a day absorption means a section/sky conventionally, but also can be more.For smear or butter, a day absorption means approximately 4 parts conventionally, 4 bread of its hypothesis mean consumption every day.Yet, lower or more a large amount part be also possible, the custom that it depends on the type of product and content and depends on consumer.
In the present invention, the scale of MK-7 is shown to milligram (meg).The present composition preferably comprise at least take in 0.1mcg MK-7/ day or/part.Preferably, described composition comprises to be taken at least 0.2mcg MK-7/ day, and more preferably took in 0.5 to 400mcg/ day or/part scope in.Suitably, according to the present invention and/or the composition of its some embodiments comprise the MK-7 within the scope of the absorption of 1 to 350mcg/ day, be more suitably to take in 2 to 300mcg/ days, more preferably 5 to 250mcg MK-7/ days were taken in, more preferably 10 to 200mcg MK-7/ days were taken in, more preferably 15 to 180mcg MK-7/ days were taken in, even more preferably 20 to 150mcg MK-7/ days were taken in, even more preferably 25 to 120mcg MK-7/ days were taken in, and more preferably took in 40 to 100mcg MK-7/ days and most preferably 50 to 90mcg MK-7/ days were taken in.Because vitamin K promotes blood clotting, it can not be supposed to, so in composition, the upper limit of MK-7 is preferably less than and takes in or every part 400mcg MK-7/ day, and is more preferably less than 200mcg MK-7 and is most preferably less than and take in 100mcg MK-7/ day.
Suitably, for can be for spoon product for example yogurt, whipping cream (creme fraiche) or dessert, the amount of MK-7 is 0.1mcg/100 gram of product at least.In a preferred embodiment of the present invention and/or its some embodiments, the amount of MK-7 is 0.2 to 400mcg/100 gram of product, more preferably 0.5 to 350mcg MK7/100 gram product, more preferably 1 to 250mcg MK7/100 gram product, more preferably 5 to 200mcg MK7/100 gram products, more preferably 10 to 150mcg MK-7/100 gram products, more preferably 20 to 100mcg MK-7/100 gram products, more preferably 40 to 90mcg MK7/100 gram products, more preferably 50 to 70mcg MK-7/100 gram products, even more preferably 9 to 90mcg MK7/100 gram products.Suitably, the amount of MK-7 is less than 200mcg/100 gram of product, is preferably less than 100mcg/100 gram of product, is preferably less than 50mcg/100 gram of product, is preferably less than 40mcg/100 gram of product, is preferably less than 20mcg/100 gram of product.
Suitably, for drink, for example breast, yogurt drink, dairy products drink, fruit drink, the amount of MK-7 is 0.1mcg/100ml product at least.In a preferred embodiment of the present invention and/or its some embodiments, the amount of MK-7 is 0.2 to 400mcg/100ml product, more preferably 0.5 to 350mcg MK7/100ml product, more preferably 1 to 250mcg MK7/100ml product, more preferably 5 to 200mcg MK7/100ml products, more preferably 10 to 150mcg MK-7/100ml products, more preferably 20 to 100mcg MK-7/100ml products, 40 to 90mcg MK7/100ml products more preferably, more preferably 50 to 70mcg MK-7/100ml products, even more preferably 6 to 60mcg MK7/100ml products.Suitably, the amount of MK-7 is less than 200mcg/100ml product, is preferably less than 100mcg/100ml product, is preferably less than 60mcg/100ml product, is preferably less than 40mcg/100ml product, is preferably less than 20mcg/100ml product.
Suitably, for the edible rat cheese of cutting into slices, the amount of MK-7 is 0.25mcg/100 gram of product at least.In a preferred embodiment of the present invention and/or its some embodiments, the amount of MK-7 is 0.5 to 1000mcg/100 gram of product, more preferably 1.5 to 900mcg MK7/100 gram products, more preferably 2.5 to 750mcg MK7/100 gram products, more preferably 10 to 500mcg MK7/100 gram products, more preferably 25 to 400mcg MK-7/100 gram products, more preferably 50 to 250mcg MK-7/100 gram products, more preferably 100 to 200mcg MK7/100 gram products, more preferably 120 to 170mcg MK-7/100 gram products, even more preferably 45 to 450mcg MK7/100 gram products.Suitably, the amount of MK-7 is less than 400mcg/100 gram of product, is preferably less than 200mcg/100 gram of product, is preferably less than 100mcg/100 gram of product, is preferably less than 60mcg/100 gram of product, is preferably less than 40mcg/100 gram of product.
Suitably, for smear for example butter, margarine, dairy products smear, cheese smear, the amount of MK-7 is 0.2mcg/100 gram of product at least.In a preferred embodiment of the present invention and/or its some embodiments, the amount of MK-7 is 0.5 to 1000mcg/100 gram of product, more preferably 1.5 to 900mcg MK7/100 gram products, more preferably 2.5 to 750mcg MK7/100 gram products, more preferably 10 to 500mcg MK7/100 gram products, more preferably 25 to 400mcg MK-7/100 gram products, more preferably 50 to 250mcg MK-7/100 gram products, more preferably 100 to 200mcg MK7/100 gram products, more preferably 120 to 170mcg MK-7/100 gram products, even more preferably 90 to 900mcg MK7/100 gram products.Suitably, the amount of MK-7 is less than 500mcg/100 gram of product, is preferably less than 400mcg/100 gram of product, preferably be less than 200mcg/100 gram of product, preferably be less than 100mcg/100 gram of product, be preferably less than 50mcg/100 gram of product, be preferably less than 30mcg MK-7/100 gram product.
When food compositions comprises that 20 to 60mcg MK-7/ days were taken in or can obtain good result when part (from the taking in day of the farnoquinone of other food products).Should be understood that in the Western countries, within average diet normal day of farnoquinone, take in as about 30mcg, this is insufficient.Vitamin K 1mainly be present in green vegetable, for example spinach, Tang's asparagus lettuce (swiss chard) and Brassica plants (Brassica) (for example, cabbage, collard (kale), cauliflower (cauliflower), broccoli (broccoli) and Brussels sprouts (brussels sprouts)); The vitamin K that for example, also has high level in some fruit (avocado, Chinese grooseberry and grape).The signal portion of the synthetic required vitamin K of people of colon bacteria; This is one of neonate's reason of conventionally accepting at birth vitamin K injection---for they are spent until the colon that is them in 5 to 7 days become when surely being grown (clonization).Methylnaphthoquinone-4 (vitamin K 2) by animal tissue, synthesized and it is present in meat, egg and dairy products.Methylnaphthoquinone-7 are during fermentation synthesized by bacterium and it is present in the soybean (natto) of fermentation.
Composition of the present invention comprises and has at least fat of 36wt% saturated fatty acid.
In the present invention, the amount of aliphatic acid provides with the percentage by weight (wt%) of TFA.In a preferred embodiment of the present invention and/or its some embodiments, described fat comprises 40 to 95wt% saturated fatty acid, more preferably 43 to 90wt% saturated fatty acid, more preferably 45 to 80wt% saturated fatty acid, more preferably 48 to 70wt% saturated fatty acid, even more preferably 52 to 68wt% saturated fatty acid, even more preferably 55 to 65wt% saturated fatty acid, even more preferably 58 to 63wt% saturated fatty acid, even more preferably 58 to 61wt% saturated fatty acid.Following table shows common first names, structural formula and the lipid number of saturated fatty acid.
The aliphatic acid that following table has provided some edible fats forms
Modal saturated fatty acid is butyric acid, laurate, myristic acid, palmitic acid and stearic acid.
The saturated fat spectrum of common food;
By the aliphatic acid through esterification of the percentage of total fat
In a preferred embodiment, saturated fatty acid is selected from laurate, myristic acid, palmitic acid and stearic acid.More preferably, saturated fatty acid is selected from myristic acid and palmitic acid.
Suitably, the fat of the present invention and/or its some embodiments for example,, than shorter saturated fatty acid (C4:0, C10:0 and C12:0), comprises longer saturated fatty acid (for example C14:0, C16:0 and C18:0).In a preferred embodiment of the present invention and/or its some embodiments, the saturated fatty acid with 1 to 12 carbon atom (C1-C12) is less than 2 with the ratio having more than the saturated fatty acid of 12 aliphatic acid (C14-30), more preferably the ratio of C1-12 and C14:30 is less than 1.5, be more preferably less than 1, even be more preferably less than 0.5, and be even more preferably less than 0.3, be more preferably less than 0.2 and be most preferably less than 0.15.
Preferably, fat of the present invention comprises the short chain saturated fatty acid with 1 to 12 carbon atom (C1-12) that is less than 40wt%, more preferably, fat of the present invention comprises the C1-12 saturated fatty acid that is less than 35wt%, even be more preferably less than the C1-12 saturated fatty acid of 30wt%, even be more preferably less than the C1-12 saturated fatty acid of 25wt%, and be more preferably less than the C1-12 saturated fatty acid of 20wt%, be most preferably less than the C1-12 saturated fatty acid of 15wt%.Percentage by weight is based on TFA.
In another preferred embodiment of the present invention and/or its some embodiments, the total amount of myristic acid and palmitic acid is greater than the 13wt% of TFA.More preferably, the total amount of myristic acid and palmitic acid is greater than the 15wt% of TFA, more preferably greater than 17wt%, more preferably greater than 20wt%, more preferably greater than 25wt%, even more preferably greater than 27wt%, and even more preferably greater than 30wt%, be most preferably greater than 33wt%.
In a preferred embodiment, described fat is selected from palm oil, palm olein, palm-kernel oil, shea nut, mist ice grass grease, cottonseed oil, coconut oil, cocoa butter, butter fat, butterfat oil, anhydrous milkfat, butterfat, lard, leaf fat, tallow, its fraction, and arbitrary composition, and preferred animal tallow.Can use any food stage animal tallow.Animal tallow is defined in the commercialization process of refining or extraction, than plant origin, available from animal origin and preferably available from mammal and/or poultry.Preferred animal tallow can be butter fat, butterfat, lard, leaf fat or its fraction.Animal tallow also comprises the fat available from mammiferous breast.In a preferred embodiment, fat is for example butterfat, butter fat, butter oil, anhydrous milkfat (AMF) of the derivative fat of breast, the sphingolipid of phosphatide and/or rich butterfat and fraction thereof.In an especially preferred embodiment, animal tallow is butter fat, butterfat and/or its fraction.Can predict the combination of saturated fat significantly.In the present invention and/or its some embodiments, also may there is the one or more of fat that contains 36wt% saturated fatty acid at least and one or more ofly contain the fatty combination that is less than 36wt% saturated fatty acid, as long as be 36wt% at least through the fatty saturated fatty acid total amount of combination.
In a preferred embodiment of the present invention and/or its some embodiments, fat does not comprise hydrogenated fat.For healthy reason, do not use hydrogenated fat, or remained minimum.In a preferred embodiment of the present invention and/or its some embodiments, the amount of hydrogenated fat is less than the 10wt% of fat phase, be more preferably less than the 8wt% of fat phase, be more preferably less than the 6wt% of fat phase, be more preferably less than the 4wt% of fat phase, even be more preferably less than the 2wt% of fat phase, be even more preferably less than the 1wt% of fat phase, and most preferably fat comprises the hydrogenated fat of 0wt% mutually.
In a preferred embodiment of the present invention and/or its some embodiments, fat comprises fish oil or other are rich in the oil of LC-PUFA (long-chain polyunsaturated fatty acid).The total amount that should be understood that saturated fatty acid should be not less than 36wt%.The preferred amounts of LC-PUFA is 1 to 1000mg/100 gram of product.The more preferably amount of LC-PUFA is 5 to 500mg/100 grams of products, 10 to 300mg/100 grams of products, 20 to 200mg/100 grams of products more preferably, 25 to 150mg/100 grams of products more preferably, more preferably 30 to 120mg/100 grams of products and most preferably be 40 to 100mg/100 grams of products.In another embodiment of the present invention and/or its some embodiments, the amount of LC-PUFA is 5 to 5000mg/ daily doses, more preferably 10 to 3000mg LC-PUFA/ daily doses, more preferably 20 to 2000mg LC-PUFA/ daily doses, more preferably 50 to 1000mg LC-PUFA/ daily doses, even more preferably 60 to 500mg LC-PUFA/ daily doses, more preferably 75 to 200mg LC-PUFA/ daily doses and most preferably 80 to 160mg LC-PUFA/ daily doses.
LC-PUFA comprises the aliphatic acid of more than one pair of key and preferably in molecule, has at least 20 carbon atoms in skeleton.This classification comprises many important compound, for example essential amino acid (for example ω-3 and ω-6 aliphatic acid and preferably omega-fatty acid).
According to the present invention and/or its some embodiments, LC-PUFA can be selected from cis-6, 9, 12-18 carbon three diluted acid (GLA, acid and gamma-linolenic), cis-11, 14, 17-eicosatrienoic acid (ETE) C20:3, cis-8, 11, 14, 17-eicosatetraenoic acid (ETA) C20:4, cis-5, 8, 11, 14, 17-eicosapentaenoic acid (EPA) C20:5, cis-7, 10, 13, 16, 19-clupanodonic acid (DPA, fish acid) C22:5, cis-4, 7, 10, 13, 16, 19-DHA (DHA) C22:6, cis-9, 12, 15, 18, 21-tetracosa carbon pentaene acid C24:5, cis-6, 9, 12, 15, 18, 21-nisioic acid (nisinic acid) C24:6, cis-11, 14-eicosadienoic acid C20:2, cis-8, 11, 14-eicosatrienoic acid (dihomo-gamma-linolenic acid) is C20:3 (DGLA), cis-5, 8, 11, 14-eicosatetraenoic acid (arachidonic acid) is C20:4 (AA), cis-13, 16-bis-dodecadienoic acid C22:2, cis-7, 10, 13, 16-docosatetraenoic acid (adrenic acid) C22:4, cis-4, 7, 10, 13, 16-EPA (this Bond's acid (Osbond acid) difficult to understand) C22:5.Most preferably EPA, DHA and/or DPA.Preferably use animal origin, particularly fish and marine product oil or algae oil in all sources of PUFA.In one embodiment of the invention, the source using the fish oil available from fish liver, catfish, mackerel, salmon, chum salmon and sardine as LC-PUFA.
According to the present invention and/or its some embodiments, in food compositions, fat preferably exists with 0.01 to 80wt% concentration, more preferably 0.1 to 60wt%, even more preferably 0.2 to 50wt%, and even more preferably 0.5 to 40wt%, and even more preferably 0.8 to 35wt%, even more preferably 1.0 to 30wt%, more preferably 1.2 to 25wt%, and more preferably 1.3 to 20wt%, and more preferably 1.5 to 15wt% and most preferably 1.8 to 13wt%.In composition of the present invention, fat preferably exists with the form of emulsion.Preferably, this emulsion is oil in water emulsion.In the situation that butter fat is used as to animal tallow, this is especially preferred.
According to the present invention and/or its some embodiments, described composition also can comprise other vitamins and/or mineral matter, emulsifying agent, colouring agent, anticorrisive agent, natural gum, thickener.If use PUFA in composition, preferably with antioxidant, prevent long-chain fat acid oxidase as vitamin C, vitamin E, selenium, polyphenol, bioflavonoid, described long-chain fat acid oxidase can cause the undesirable changing odor of product and short shelf-life.
In a preferred embodiment of the present invention and/or its some embodiments, described composition also comprise vitamin D and, preferably, neo dohyfral D3.The amount of vitamin D can be to be taken in 0.25 to 6mcg/ day, and preferably 0.5 to 5mcg/ day was taken in, and more preferably 1 to 4mcg/ day was taken in, more preferably 1.2 to 3.5mcg/ days were taken in, more preferably 1.5 to 3mcg/ days were taken in, and more preferably 1.7 to 2.5mcg/ days were taken in, and more preferably 2 to 2.2mcg/ days were taken in." vitamin D " used herein refers to, any form known of vitamin D, and comprise especially calciferol (ergocalciferol), neo dohyfral D3 (cholecalciferol), vitamin D Precursors, metabolin and other analogs, and combination, and various activity and the inactive form of vitamin D.For example, the inactive form that neo dohyfral D3 can be provided as to its non-hydroxylated, as cholecalciferol, maybe can be provided as its hydroxylated activity form as calcitriol.
In a preferred embodiment of the present invention and/or its some embodiments, described composition comprise vitamin D and, the preferred neo dohyfral D3 of the amount of 0.25mcg to 15mcg/100 gram or 100ml product, more preferably 0.5 to 12mcg/100 gram or 100ml, more preferably 1 to 10mcg/100 gram or 100ml, more preferably 1.2 to 8mcg/100 grams or 100ml, more preferably 1.5 to 6mcg/100 grams or 100ml, more preferably 1.7 to 5mcg/100 grams or 100ml, more preferably 2 to 4mcg/100 grams or 100ml, more preferably 2.5 to 3.5mcg/100 grams or 100ml, and most preferably 2.7 to 3.2mcg/100 grams or 100ml.
In another preferred embodiment of the present invention and/or its some embodiments, described composition comprises cobalamin (various cobalamin).This vitamin contributes to energetic supersession, red blood cell formation, immune function and mental health.In people and especially, in the elderly, unfavorable blood level is quite general, because the absorption increasing via enteron aisle along with the age reduces.Low cobalamin blood level causes macrocytic anemia, makes the homocystine of the rising that the risk of angiocardiopathy, peripheral nerve disease, memory loss and other cognitive defects raises.The preferred amounts of cobalamin is 0.25 to 3mcg, and preferably 0.375 to 2mcg/ day was taken in.
In a preferred embodiment of the present invention and/or its some embodiments, described composition also can comprise mineral matter for example calcium and/or magnesium and/or potassium.These mineral matters can be to causing the muscle function of for example adjusting of heartbeat, artery diameter, blood pressure and/or blood flow to have beneficial effect.Should be understood that any form in the food stage source that can use calcium, magnesium and potassium.These comprise organic and inorganic compound, salt, molecular complex, chelate, such as calcium citrate, calcium carbonate, calcium gluconate, calcium lactate, calcium phosphate, magnesia, magnesium citrate etc.For magnesium, preferred source is magnesium citrate.About calcium, dairy products or milk composition (especially breast and a newborn part) are the examples of calcium appropriate sources.
In a preferred embodiment of the present invention and/or its some embodiments, calcium (Ca) is preferably present in composition of the present invention, and its amount is 20 to 1600mg, and preferably 70 to 1000mg, more preferably, 80 to 800mg/ days were taken in.In the present composition, the preferred amounts of Ca is to take in 100 to 600mg/ days.
In a preferred embodiment of the present invention and/or its some embodiments, the amount of calcium is 20 to 4000mg/100 grams or 100ml product, more preferably 70 to 2500mg/100 grams or 100ml, more preferably 80 to 2000mg/100 grams or 100ml, more preferably 100 to 1500mg/100 grams or 100ml, more preferably 150 to 1250mg/100 grams or 100ml, more preferably 200 to 1000mg/100 grams or 100ml, more preferably 250 to 800mg/100 grams or 100ml, more preferably 300 to 600mg/100 grams or 100ml, more preferably 400 to 500mg/100 grams or 100ml.
The content of magnesium (Mg) is preferably 20 to 800mg, and more preferably 30 to 500mg, and even more preferably 50 to 300mg/ days were taken in.In a preferred embodiment of the present invention and/or its some embodiments, described composition comprises 80 to 800mg calcium and 50 to 300mg magnesium/day is taken in.
In a preferred embodiment of the present invention and/or its some embodiments, the amount of magnesium is 20 to 2000mg/100 grams or 100ml product, more preferably 30 to 1500mg/100 grams or 100ml, more preferably 50 to 1000mg/100 grams or 100ml, more preferably 80 to 750mg/100 grams or 100ml, more preferably 100 to 500mg/100 grams or 100ml, more preferably 150 to 250mg/100 grams or ml.In a preferred embodiment of the present invention and/or its some embodiments, described composition comprises 80 to 2000mg calcium and 50 to 750mg magnesium/100 gram or 100ml product.
In a preferred embodiment, if composition of the present invention is dairy compositions, this dairy compositions is unique source of Ca, in other words, and need not supplement said composition by extra Ca.Therefore, in this embodiment, Ca is on close level in the level of Ruzhong Ca, in other words, is 50 to 200mg/100g, or 60 to 400mg/ parts.In this situation, take in the day of Ca and be preferably 80 to 800mg, more preferably, 100 to 700mg, and even more preferably 120 to 600mg, and particularly preferably 240 to 500mg.Yet, in another preferred embodiment of the present invention and/or its some embodiments, can supplement with extra calcium the total amount that this dairy compositions exists calcium, for example, be 100 to 1200mg, and preferably 120 to 1000mg and even more preferably 240 to 800mg/ days were taken in.
Yet, in another preferred embodiment of the present invention and/or its some embodiments, can supplement with extra calcium this dairy compositions makes to such an extent that the total amount that exists of calcium is, for example, 100 to 3000mg, more preferably 120 to 2500mg, more preferably 240 to 2000mg calcium/100 gram or 100ml product.
In another preferred embodiment of the present invention and/or its some embodiments, the Ca/Mg ratio of described composition is not more than 8 and be more preferably not more than 6, and for example 5 or less.Yet more preferably,, Ca/Mg ratio is not more than 3.5 and even more preferably, is not more than 3.The preferable range of Ca/Mg ratio is 0.5 to 2.7.Ca/Mg ratio in 1.5 to 2.4 scopes is particularly preferred, for example, and approximately 2.Low Ca/Mg ratio relates to independently every kind of product or every part.
In another preferred embodiment of the present invention and/or its some embodiments, the amount that potassium (K) is preferably taken in 50 to 2000mg/ days is present in composition of the present invention, more preferably 100 to 1000mg potassium/day is taken in, more preferably 150 to 800mg K/ days were taken in, and even more preferably took in 200 to 700mg K/ days and most preferably 250 to 600mg K/ days were taken in.
In another preferred embodiment of the present invention and/or its some embodiments, the amount of potassium is 50 to 5000mg, more preferably 1000 to 2500mg, more preferably 150 to 2000mg, even more preferably 200 to 1750mg, and more preferably 250 to 1500mg, and more preferably 300 to 1000mg, more preferably 400 to 800mg, more preferably 500 to 600mg potassium/100 gram or 100ml product.
In another preferred embodiment of the present invention and/or its some embodiments, composition of the present invention also can comprise at least one breast or from composition of milk.Think that in this case said composition is dairy compositions.These compositions can be for example casein and lactalbumins (for example lactoalbumin and lactoglobulin) of lactoprotein, it comprises the casein of hydrolysis and lactalbumin, caseinate, also has lactose, curdled milk, milk powder, milk solids, butter solid, butterfat oil, butter fat, lactic acid, recaldent.In addition breast and for example, being included in term dairy compositions based on breast or the product (milk product of emulsifiable paste, cheese, milk powder, sauce (sauce), yogurt, fermentation) by newborn processing acquisition.In this embodiment, fat can be only butter fat and/or butterfat or with the combination of other fat.
In a particularly preferred embodiment of the present invention and/or its some embodiments, described food compositions is yogurt, and it can be spoon by denseness or is drink form.Gross weight based on composition, yogurt of the present invention preferably comprises 0.01 to 10wt% fat, and preferably 1 to 5wt%, and more preferably 1 to 3wt%, and more preferably 1.2 to 2wt% and most preferably 1.5 to 1.8wt%.
In another preferred embodiment of the present invention and/or its some embodiments, described food compositions is cheese.In cheese situation, milk fermentation product mean to comprise soft and hard cheese the two.The example of cheese is Ai Damu cheese (Edam cheese), up to cheese (Gouda cheese), Switzerland's cheese cheese (emmental), cheese cheese (brie) in cloth, camembert (camembert), cut and reach cheese (cheddar), soft cheese (cottage cheese), low fat cheese, cream cheese, smear cheese, fresh milk junket, Mo Zeleile cheese (mozzarella), goat milk cheese (feta), Maas card pool Buddhist nun's cheese (mascarpone), Pa Masen cheese (parmezan).Gross weight based on composition, cheese of the present invention preferably comprises 3 to 75wt.% fat, and preferably 20 to 60wt.%.
In another preferred embodiment of the present invention and/or its some embodiments, described composition is breast, cream or newborn base drink.These example comprises whipped cream, contains fruit juice milk beverage, the milk product of fermentation, coffee milk, newborn blend.Gross weight based on said composition, breast of the present invention, cream or the drink based on newborn preferably comprise 0.05 to 35wt.% fat, preferably 0.1 to 30wt.%, more preferably 0.5 to 25wt%, more preferably 1 to 20wt%, more preferably 1.2 to 15wt%, and more preferably 1.3 to 12wt%, and most preferably 1.5 to 10wt%.
Said composition can also be ice cream, acidified milk, whipped cream (whipped cream), butter breast, milk oil base sauce, condensed milk, pudding, yogurt oil, whipping cream custard, and/or dairy products smear.
On the other hand, the present invention relates to according to the present invention and/or the preparation method of the composition of its some embodiments, it comprise by vitamin(e) M K-7 with comprise at least fat combination of 36wt% saturated fatty acid, and optionally MK-7 is added in food product.Can prepare according to composition of the present invention by any mode easily known to those skilled in the art.In a preferred embodiment, thus by the animal tallow of the MK-7 of appropriate sources and appropriate sources is added, in food product, prepare composition of the present invention and preferably obtain dairy compositions.Under appropriate sources, should be understood that source (for example compound or composition) comprises vitamin or the key element of expectation, described source is suitable in food product (food stage).Preferably, appropriate sources comprises MK-7 that can biological utilisation form, for example chelated forms or as acylate.Animal origin is more more preferred than plant origin.Suitably MK-7 is added in the premix of vitamin and/or mineral matter.Equally suitably MK-7 is added in fruit prepared product and/or fruit sugar syrups.Then fruit prepared product and/or syrup are added in food compositions.
Can these compositions be mixed by the mode of any routine known to those skilled in the art.For example, MK-7 can be dissolved in the fatty fat of bag mutually in, the available optional water emulsification subsequently and/or be added in food product to be strengthened mutually of described fat.MK-7 can also be used and be added in the residual components of water by powder type, or is added directly in product.
In a further aspect, the present invention relates to according to the present invention and/or the composition of its some embodiments, it is selected from vascular health for supporting and/or maintaining and/or improve, cardiovascular health, the systemic circulation of blood, the microcirculation of blood, hemoperfusion, blood vessel elasticity, bone health, blood coagulation ability, platelet aggregation ability, glucose is controlled, insulin secretion, insulin sensitivity, mental health, cognitive performance, memory, vigilant, spirit acuity, Weight management, triglyceride levels in blood, blood pressure, BMI, and/or the situation of waistline and/or for preventing diabetes, fat, metabolic syndrome, artery sclerosis, chronic inflammation and/or mild inflammation.
In aspect another, the present invention relates to be used for the treatment of be selected from following illness according to the present invention and/or the composition of its some embodiments: vascular diseases, angiocardiopathy, atherosclerotic, obstruction of artery, blood vessel lack flexibility (vessel inflexibility), varication, TIA (transient ischemic attack, TIA), bone disease, bone demineralisation, osteoporosis, thrombosis, palsy, diabetes, insulin resistance, high triglyceride blood level, metabolic syndrome, fat, body fat amount is piled up, high waistline, hypertension, chronic inflammation, mild inflammation, mental illness, spirit goes down, dementia and/or Alzheimer disease.
Another aspect of the present invention also relates to according to the present invention and/or the composition of its some embodiments is selected from vascular health for supporting and/or maintaining and/or improve, cardiovascular health, blood vessel elasticity, blood pressure, blood flow, blood circulation, the systemic circulation of blood, the microcirculation of blood, hemoperfusion, bone health, blood coagulation ability, platelet aggregation ability, glucose is controlled, insulin secretion, insulin sensitivity, mental health, cognitive performance, vigilant, memory, with the situation of spiritual acuity and/or for preventing to be selected from diabetes, fat, metabolic syndrome, artery sclerosis, the purposes of chronic inflammation and/or subinflammatory illness.
Another aspect of the present invention relate to according to the present invention and/or the composition of its some embodiments for improving the bioavilability of vitamin K and/or farnoquinone and/or MK-7, and/or improve the biologically active of vitamin K and/or farnoquinone and/or MK-7, and/or the purposes of the level of vitamin K and/or farnoquinone and/or MK-7 in mammalian.
The inventor finds unexpectedly, when vitamin K is in the composition with the fat that is less than 36wt% saturated fatty acid, comprises and there is at least fatty composition of 36wt% saturated fatty acid and make vitamin K level in blood raise sooner and reach higher level.The vitamin K fill-in using in prior art comprises liquid vegetable oil conventionally, for example sunflower, soybean, natto, linseed and/or olive oil.Discovery for example, under farnoquinone (56mcg/ days) condition of reduced levels, and in blood, farnoquinone level reaches conventionally the level reaching when using almost twice in the amount of farnoquinone used.The present invention allows to use the farnoquinone of lower amount to realize effect same as the prior art.Because farnoquinone participates in blood clotting, so expectation has the vitamin K compared with low dosage.
Another aspect of the present invention also relate to according to the present invention and/or the composition of its some embodiments for reducing not carboxylation MGP and/or the not purposes of the cyclical level of carboxylation osteocalcin in mammalian.
Another aspect of the present invention relate to according to the present invention and/or the composition of its some embodiments for improving the purposes of the cyclical level of mammalian carboxylation MGP and/or carboxylation osteocalcin.
In a preferred embodiment of the present invention and/or its some embodiments, in 12 weeks, preferably in 8 weeks, more preferably obtained in 4 weeks: not carboxylation MGP and/or the not reduction of the cyclical level of carboxylation osteocalcin in mammalian, and/or the rising of the level of vitamin K and/or farnoquinone and/or MK-7 in the rising of the cyclical level of carboxylation MGP and/or carboxylation osteocalcin and/or mammalian.
As the higher level of vitamin K in the blood by the present invention obtained cause not carboxylation MGP and/or not carboxylation osteocalcin reduce.The not carboxylation form of MPG and osteocalcin is the inactive form of these protein.Think that the carboxylation form of MPG and osteocalcin is relevant to cardiovascular health.Using the present composition after 4 weeks, observe not carboxylation MGP and not carboxylation osteocalcin significantly reduce.
In one aspect of the method, the invention still further relates to by by according to the present invention and/or the composition of its some embodiments be applied to mammal and reduce not carboxylation MGP and/or the not method of the cyclical level of carboxylation osteocalcin in mammalian.
In addition, another aspect of the present invention relate to by by according to the present invention and/or the composition of its some embodiments be applied to the method that mammal is improved the cyclical level of carboxylation MGP in mammalian and/or carboxylation osteocalcin.
Another aspect of the present invention relate to by by according to the present invention and/or the composition of its some embodiments be applied to the method that mammal is improved the level of vitamin K in mammalian and/or farnoquinone and/or MK-7.
Preferably, according to the present invention and/or in the method and/or purposes of its some embodiments, by according to the present invention and/or the composition of its some embodiments use time at least 4 weeks, preferably at least 8 weeks, most preferably at least 12 weeks.Preferably, product of the present invention is applied to the lifelong of people, suitably, this product is used to 1,2,3,5,7,10,12,15,18,20,23,25,27,30,32,35,38,40,45,50,55,60,65,70,75,80,85,90 or as many as time of 95 years even.
To in following non-limiting example, to the present invention, further illustrate.
embodiment 1: with the yogurt drink and the breast that are supplemented with farnoquinone, intervene for a long time.
During 1 year, amount to that 38 postclimacteric women accept to contain 1.5wt% to 2wt% butterfat (wherein 66wt% is saturated fat) every day, approximately two kinds of dairy products (1 part of breast (250ml) and 1 portion of yogurt) of 3wt% protein and about 10 grams of carbohydrate and its have been rich in total 100mcg farnoquinone (MK-7), 10mcg neo dohyfral D3 and 800mg Ca.
Before between intervention period and gather afterwards blood sample for vitamin K analysis.According to Schurgers and Vermeer, Haemostasis, 2000:30, described in 299-307, to the vitamin K analysis of circulating in serum.Briefly, with hexane, extract blood serum sample and after prepurification, utilize silica column to pass through high performance liquid chromatography (HPLC) it is analyzed.For HPLC, use to there is the reversed-phase column of online zinc reduction and fluoroscopic examination and by the vitamin K (vitamin K of synthesized form 1-25) as internal reference.
As the result of intervening, in blood, the level of farnoquinone is increased to 4.1ng/ml by 0.64ng/ml (control level, before intervention).After dairy products consumption (4.1ng/ml), this farnoquinone blood level is significantly higher than based on using the soft gel (oil capsule that saturated fatty acid is low; Lower than 16%) in the expection of delivering research intervened of farnoquinone.In other words, based on comparable vitamin K picked-up level, these levels are (Theuwissen etc., Br J.Nutr.2012 1-5 page in the scope of 1.7ng/ml to 3.3ng/ml; Schurgers etc., Blood 2007; 109:3279-3283).
embodiment 2: the yogurt drink of the every daily 56mcg of being supplemented with farnoquinone carries out people's intervention
During 12 weeks, 27 healthy males of 45 to 65 years old and postclimacteric women accept 2 kinds of eutrophic yogurt products (every kind of 250ml, so amount to 500ml every day) every day.Every 100ml dairy products matrix comprises 3 grams of protein, 1.5 grams of fat (wherein 66% is saturated fat), 10 grams of carbohydrate (sugar of lactose and interpolation).In addition, every 100ml product is rich in farnoquinone (11,25 microgram), ω-3 eicosapentaenoic acid (EPA) and the DHA (DHA) of MK-7 form; 40mg EPA+DHA, calcium (120mg), magnesium (56,25mg), vitamin C (12mg) and neo dohyfral D3 (0.75 microgram).
When starting and after 4,8 and 12 weeks, gather blood sample.In research, start the last fortnight (14 days) until final blood collection, (in other words require participant to limit its every day containing vitamin K takes in, without curdled milk or soft cheese (cottage cheese)), maximum a slice cheese every day (± 30 grams) and maximum 200 grams of green vegetables.With which, make to keep constant from the normal daily consumption of the farnoquinone of other food products (estimate 30 micrograms).In addition, require object during studying, do not change their sports level or use alcohol.In addition, instruct object to keep stable body weight; Therefore in each research access, body weight is measured.
According to Schurgers and Vermeer, Haemostasis; 2000:30, analyzes the circulation vitamin K in serum described in 299-307.
The result of this research is as follows.Before intervention in serum the level of farnoquinone (MK7) according to be measured as 0.5 to 0.7ng/ml and be 2.7ng farnoquinone (MK-7)/ml serum after within 12 weeks, intervening.Based on MK-7 preparation in the lower oil capsule of known saturated fat levels (based on similar farnoquinone amount in food, be estimated as 1.4-1.7ng/ml) early stage result of study, it exceeds expection approximately 40% to 50% (Theuwissen, E etc., Br J.Nutr.2012; Schurgers etc., Blood 2007; 109:3279-3283).In addition, will be rich in after the milk product picked-up of farnoquinone, the farnoquinone of raising (MK-7) serum levels causes the remarkable effect of farnoquinone.The farnoquinone oil capsule of prior art (< 16% saturated fat) is really not so.In the prior art, use low-level farnoquinone oil capsule (45 to 90 micrograms/daily dose), after picked-up in three months, can't detect remarkable result (Theuwissen, E etc., Br J.Nutr.2012).
By make biochemical marker not the carboxylation MGP (dp-ucMGP) of phosphorylation-not and not carboxylation osteocalcin (ucOC) a plurality of time points (t=0,4,8 and 12 weeks) that circulate measure effect.Especially, Dp-ucMGP is vascular health and arteriosclerotic biomarker, yet now ucOC has been regarded as to more common healthy mark, and it comprises bone health, glucose control, lipid blood level, weight management and metabolic syndrome.The activation of protein osteocalcin (ostecalcin) needs farnoquinone.Active osteocalcin is relevant with bone mineralising and calcium homeostasis.It serves as hormone and regulates for example generation storage to fat in the susceptibility of insulin and reduction mammal with raising health of insulin.
What is interesting is, compare with the farnoquinone preparation in the sunflower oil more early recording, the milk product that is rich in MK-7 causes significantly and the faster effect (referring to table 1 and 2) of farnoquinone.After the low dosage with 56mcg MK-7 4 weeks, the milk product that is rich in MK-7 causes the remarkable change of ucOC and dp-uc MGP mark: than the MK-7 preparation of (< 16% saturated fat) of oil capsule in prior art, more high dose and/or longer open-assembly time are to detect (Theuwissen to remarkable result, E etc., Br J.Nutr.2012).
In healthy male and women (n=27) with being rich in serum ucOC level after the milk product intervention of farnoquinone
The ucOC (ng/ml) of each time point (week) Mean value ± standard deviation
t＝0 3.57±1.93
t＝4 3.01±1.87＊
t＝8 2.75±1.71＊
t＝12 2.50±1.63＊
* the conspicuousness p < 0.01 of (t=0) serum levels when initial between intervention period
In healthy male and women (n=27) with being rich in serum dp-uc MGP level after the milk product intervention of farnoquinone
Each time point (week) Dp-Uc MGP (pM) Mean value ± standard deviation
t＝0 481.2±210.5
t＝4 417.1±189.6＊
t＝8 392.6±169.4＊
t＝12 371.4±141.1＊
The conspicuousness p < 0.01 of (t=0) serum levels when * initial than intervention period
embodiment 3: with yogurt drink or the sunflower factice of the farnoquinone that comprises MK-7 form capsule is intervened
People's intervention study 45, to healthy male and the postmenopausal women of 65 years old, has 32 to 37 object/arms to accept at random 3 types of 50mcg farnoquinones (MK-7) in matrix in amounting to 105 objects.
Described different substrates is:
(1) the MK-7 replenishers in sunflower oil capsule (50 microgram),
(2) MK-7 (50 microgram) in yogurt drink (3% protein, 1.5% fat (wherein 66wt% is saturated fat), 10% carbohydrate (sugar of lactic acid and interpolation)) or
(3) yogurt matrix (3% protein, 1.5% fat (wherein 66wt% is saturated fat), is added with 10% carbohydrate (sugar of lactic acid and interpolation) of ω-3 eicosapentaenoic acid (EPA) and DHA (DHA); 40mg EPA+DHA/100ml), calcium (120mg/100ml), magnesium (56.25mg/100ml), vitamin C (12mg/100ml) and neo dohyfral D3 (0.75 microgram/100ml)) in MK-7 (50 microgram).
Generally, during six weeks, every daily consumption 450ml dairy products drink or by MK-7 capsule consumption.When beginning and after 2 weeks, 4 weeks and 6 weeks, gather blood sample.In latter 3 days of intervention, t=1 week and t=2 week (removing phase), gather blood sample equally.According to Schurgers and Vermeer, Haemostasis; 2000:30, described in 299-307 to the circulation vitamin K in serum, not carboxylation osteocalcin (ucOC), carboxylation osteocalcin (cOC), dephosphorylation and not carboxylation matrix Gla protein (dp-uc MGP) analyze.
As the result of intervening, in the time of 4 weeks, serum detected in the significant difference of MK-7 level between dairy products and replenishers.In addition, the change of biochemical marker depends on treatment: for dp-uc MGP, the MK-7 in MK-7 replenishers (group 1), yogurt (group 2) and the change with MK-7 in extra nutraceutical yogurt matrix (organizing 3) are respectively 58pM, 73pM and 99pM.For cOC, MK-7 replenishers not shown result for the treatment of, however two kinds of yogurt products are significantly effective in the carboxylation level that improves farnoquinone dependence.The significant difference of cOC is shown between 3 (about thering are extra ω-3, neo dohyfral D3, Ca, Mg and ascorbic dairy products) of group and MK-7 replenishers.Therefore, consistent with research before this, these dairy products are rich in MK-7, and particularly these dairy products have extra ω-3, neo dohyfral D3, Ca, Mg and vitamin C, and it is compared the MK-7 replenishers that are dissolved in sunflower oil and has provided better result.Therefore, compare with the MK-7 replenishers that are dissolved in sunflower oil (having low-level saturated fat (11%)), the product that is rich in MK-7 with high saturated fat level provides better result.These results illustrate food substrate (and particularly the content of saturated fat) to the bioavilability of farnoquinone (particularly MK-7) and active impact.
In healthy male and women (group 2 and group 3) with replenishers (group 1) be rich in after the dairy products intervention of farnoquinone the serum MK-7 level of MK-7 level (than initial) and TG-AUC (AUC) (in ng/ml) variation
* by thering is the linear regression of check baseline value, age, sex, BMI, test difference between group (group 1 and group 2) (p < 0.05)
# tests difference between group (group 1 and group 3) (p < 0.05) by having the linear regression of check baseline value, age, sex, BMI
The level of biochemical marker after different treatments in 6 weeks.
* by paired samples t, check to test than difference (p < 0.05) in the group of baseline
# tests difference between group (p < 0.05) by having the ANOVA of Boniferroni correction
Fig. 1 is illustrated in via replenishers (blueness), via having, comprises the extra nutraceutical yogurt matrix (redness) of ω-3, vitamin C, neo dohyfral D3, Ca and Mg and via the supplementary rear circulation dp-ucMGP of the picked-up level (with the mean value of SE, in pM) of the farnoquinone of yogurt drink (green).
Fig. 2 is illustrated in via replenishers (blueness), via having, comprises the extra nutraceutical yogurt matrix (redness) of ω-3, vitamin C, neo dohyfral D3, Ca and Mg and via the level (with the mean value of SE, in ng/ml) of the supplementary rear circulation cOC of picked-up of the farnoquinone of yogurt drink (green).

Claims (20)

1. a food compositions, it comprises fat and farnoquinone, and wherein said fat comprises at least 36% saturated fatty acid, and wherein said farnoquinone is the MK-7 form of at least 0.1mcg MK-7/ daily intaking amount.
2. composition according to claim 1, wherein said fat is selected from and comprises following group: palm oil, palm olein, palm-kernel oil, shea nut, mist ice grass grease, cottonseed oil, coconut oil, cocoa butter, butter fat, butterfat, butterfat oil, AMF, lard, leaf fat, tallow, its fraction, and any combination, and be preferably animal tallow.
3. composition according to claim 1 and 2, it also comprises breast or from composition of milk.
4. according to composition in any one of the preceding claims wherein, the lactalbumin of its casein that comprises casein, lactoalbumin, lactoglobulin, hydrolysis, hydrolysis, caseinate, lactose, curdled milk, milk powder, milk solids, butter solid, butterfat oil, lactic acid and/or recaldent.
5. according to composition in any one of the preceding claims wherein, it comprises took in 0.20 to 400mcg vitamin(e) M K-7/ day.
6. according to composition in any one of the preceding claims wherein, it also comprises and is selected from the composition that comprises following group: calcium, magnesium, potassium, polyunsaturated fatty acid and vitamin D.
7. prepare according to a method for composition described in any one in aforementioned claim, it comprises vitamin(e) M K-7 and comprises at least fat of 36wt% saturated fatty acid and be added into food product.
8. according to the composition described in any one in claim 1 to 6, it is for supporting and/or maintaining or improve the situation that comprises following group that is selected from: vascular health, cardiovascular health, blood flow, blood circulation, the systemic circulation of blood, the microcirculation of blood, the hemoperfusion of tissue, blood vessel elasticity, bone health, blood coagulation ability, orthoplastocyte agglutinability, glucose is controlled, insulin secretion, insulin sensitivity, mental health, cognitive performance, memory, vigilant, spirit acuity, Weight management, triglyceride levels in blood, blood pressure, BMI and/or waistline, and/or for preventing diabetes, fat, metabolic syndrome, artery sclerosis, chronic inflammation and/or mild inflammation.
9. according to the composition described in any one in claim 1 to 6, it is used for the treatment of and is selected from the illness that comprises following group: vascular diseases, angiocardiopathy, atherosclerotic, obstruction of artery, blood vessel lacks flexibility, varication, artery sclerosis, TIA, cold limbs, bone disease, bone demineralisation, osteoporosis, thrombosis, palsy, diabetes, insulin resistance, high triglyceride blood level, metabolic syndrome, fat, the accumulation of body fat amount, high waistline, hypertension, chronic inflammation, mild inflammation, mental illness, spirit goes down, dementia and/or Alzheimer disease.
According to the composition described in any one in claim 1 to 6 for supporting and/or maintaining or improve the situation that comprises following group that is selected from: vascular health, cardiovascular health, blood flow, blood circulation, the systemic circulation of blood, the microcirculation of blood, the hemoperfusion of tissue, blood vessel elasticity, bone health, blood coagulation ability, orthoplastocyte agglutinability, glucose is controlled, insulin secretion, insulin sensitivity, mental health, cognitive performance, memory, vigilant, spirit acuity, Weight management, triglyceride levels in blood, blood pressure, BMI and/or waistline, and/or for preventing diabetes, fat, metabolic syndrome, artery sclerosis, chronic inflammation and/or subinflammatory purposes.
11. according to the composition described in any one in claim 1 to 6 for improving the purposes of bioavilability of vitamin K and/or farnoquinone and/or MK-7.
12. are used for improving the bioactive purposes of vitamin K and/or farnoquinone and/or MK-7 according to the composition described in any one in claim 1 to 6.
13. according to the composition described in any one in claim 1 to 6 for improving the purposes of level of mammalian vitamin K and/or farnoquinone and/or MK-7.
14. according to the composition described in any one in claim 1 to 6 for reducing not carboxylation MGP and/or the not purposes of the cyclical level of carboxylation osteocalcin in mammalian.
15. according to the composition described in any one in claim 1 to 6 for improving the purposes of cyclical level of mammalian carboxylation MGP and/or carboxylation osteocalcin.
16. according to the purposes described in any one in claim 13,14 or 15, wherein in 12 weeks, preferably in 8 weeks, more preferably obtained in 4 weeks: not carboxylation MGP and/or the not reduction of the cyclical level of carboxylation osteocalcin in mammalian, and/or the rising of the cyclical level of carboxylation MGP and/or carboxylation osteocalcin in mammalian, and/or the rising of vitamin K level in mammalian.
17. 1 kinds by reducing not carboxylation MGP and/or the not method of the cyclical level of carboxylation osteocalcin in mammalian to administration according to the composition described in any one in claim 1 to 6.
18. 1 kinds by improving the method for the cyclical level of carboxylation MGP in mammalian and/or carboxylation osteocalcin according to the composition described in any one in claim 1 to 6 to administration.
19. 1 kinds by improving the method for vitamin K level in mammalian according to the composition described in any one in claim 1 to 6 to administration.
20. according to the method described in any one in claim 17,18 and/or 19, wherein according to the composition described in any one in claim 1 to 6, uses at least 4 weeks, preferably at least 8 weeks and time at least 12 weeks most preferably.
CN201380014323.XA 2012-02-15 2013-02-15 Food composition comprising vitamin k and saturated fat and its use Pending CN104168772A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2008294A NL2008294C2 (en) 2011-05-20 2012-02-15 Food composition comprising vitamin k and saturated fat.
NL2008294 2012-02-15
PCT/NL2013/050091 WO2013122465A1 (en) 2012-02-15 2013-02-15 Food composition comprising vitamin k and saturated fat and its use

Publications (1)

Publication Number Publication Date
CN104168772A true CN104168772A (en) 2014-11-26

Family

ID=47901277

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380014323.XA Pending CN104168772A (en) 2012-02-15 2013-02-15 Food composition comprising vitamin k and saturated fat and its use

Country Status (7)

Country Link
EP (1) EP2814327A1 (en)
CN (1) CN104168772A (en)
EA (1) EA028555B1 (en)
HK (1) HK1202227A1 (en)
NL (1) NL2008294C2 (en)
PH (1) PH12014501830A1 (en)
WO (1) WO2013122465A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107136514A (en) * 2017-05-23 2017-09-08 深圳泰乐德营养与健康有限公司 One kind is by vitamin D, K and vitamin B12The nutrient composition of composition
CN110122866A (en) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis
WO2021000246A1 (en) * 2019-07-02 2021-01-07 广东双骏生物科技有限公司 Bacillus subtilis natto and method for producing protein mk-7

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103431277B (en) * 2013-08-31 2014-08-27 山东卫康生物医药科技有限公司 Mixed-grain total-nutrition formulation food for traumatic or surgical patients
CN103431276A (en) * 2013-08-31 2013-12-11 山东卫康生物医药科技有限公司 Mixed-grain total-nutrition formulation food for patients with inflammatory bowel diseases
CN103431260B (en) * 2013-08-31 2014-08-20 山东卫康生物医药科技有限公司 Mixed-grain full-nutrition formulation food for patients with gastrointestinal tract malabsorption and pancreatitis
EP2886129A1 (en) * 2013-12-20 2015-06-24 VitaK B.V. Prevention and counteraction of diet-induced thrombosis risk
WO2016131993A2 (en) 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function
GB201520189D0 (en) * 2015-11-16 2015-12-30 Kappa Bioscience As Compound for use
CN106551227A (en) * 2016-11-25 2017-04-05 南昌理工学院 A kind of preparation method of Red Army's dish active function beverage

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1119500A (en) * 1995-08-23 1996-04-03 韩彬 Nutritious food sauce for baby
CN1316903A (en) * 1998-07-08 2001-10-10 丽珀詹尼克丝公司 Compositions and methods for treating and preventing bone diseases using tocotrienols
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
CN1826059A (en) * 2003-06-30 2006-08-30 大塚制药株式会社 Composition containing lactic acid bacterium producing equol
CN101534807A (en) * 2006-07-14 2009-09-16 纳多制药股份公司 Pharmaceutical and nutraceutical products comprising vitamin k2
CN101534796A (en) * 2006-10-31 2009-09-16 株式会社钟化 Physiologically active substance-containing granular composition and method of producing the same
CN101969792A (en) * 2008-01-28 2011-02-09 菲仕兰产品有限责任公司 Methods and compositions for the treatment of bone conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1132787A (en) * 1997-07-23 1999-02-09 Kikkoman Corp Production of menaquinone-containing product, and food and drink containing the same product
GB0220182D0 (en) * 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
US20100048704A1 (en) * 2006-07-14 2010-02-25 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1119500A (en) * 1995-08-23 1996-04-03 韩彬 Nutritious food sauce for baby
CN1316903A (en) * 1998-07-08 2001-10-10 丽珀詹尼克丝公司 Compositions and methods for treating and preventing bone diseases using tocotrienols
CN1826059A (en) * 2003-06-30 2006-08-30 大塚制药株式会社 Composition containing lactic acid bacterium producing equol
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
CN101534807A (en) * 2006-07-14 2009-09-16 纳多制药股份公司 Pharmaceutical and nutraceutical products comprising vitamin k2
CN101534796A (en) * 2006-10-31 2009-09-16 株式会社钟化 Physiologically active substance-containing granular composition and method of producing the same
CN101969792A (en) * 2008-01-28 2011-02-09 菲仕兰产品有限责任公司 Methods and compositions for the treatment of bone conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
熊友廉 等: "《有趣的生物世界》", 30 November 1999, article "食用菌与食物结构改善", pages: 286-287 *
罗林枝 等: "维生素K与骨质疏松", 《中国医学科学院学报》, vol. 25, no. 3, 30 June 2003 (2003-06-30), pages 346 - 349 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107136514A (en) * 2017-05-23 2017-09-08 深圳泰乐德营养与健康有限公司 One kind is by vitamin D, K and vitamin B12The nutrient composition of composition
CN107136514B (en) * 2017-05-23 2021-02-26 深圳奥萨制药有限公司 A health food containing vitamin D, K and vitamin B12Composed nutrient composition
CN110122866A (en) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 A kind of the special medicine purposes food and preparation method of chronic kidney disease angiosteosis
WO2021000246A1 (en) * 2019-07-02 2021-01-07 广东双骏生物科技有限公司 Bacillus subtilis natto and method for producing protein mk-7

Also Published As

Publication number Publication date
HK1202227A1 (en) 2015-10-30
EP2814327A1 (en) 2014-12-24
EA201491489A1 (en) 2015-01-30
PH12014501830A1 (en) 2014-11-10
NL2008294C2 (en) 2013-08-19
WO2013122465A1 (en) 2013-08-22
EA028555B1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CN104168772A (en) Food composition comprising vitamin k and saturated fat and its use
RU2606767C2 (en) Composition containing vitamin k2
RU2516782C2 (en) Liquid enteral nutrient composition suitable for enteral feeding, minimising upper and lower gastrointestinal complications
Elmadfa et al. Fats and fatty acid requirements for adults
DE69935995T2 (en) POLYUNGATURATED FATTY ACIDS NUTRITIONAL SUPPLEMENT
JP4031219B2 (en) Oil composition
US20100197785A1 (en) Omega-3 fatty acid fortified composition
JP2004519253A (en) Liquid egg products
Gurr Lipids and nutrition
AU2002325344A1 (en) Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lilpid level
WO2003013276A1 (en) Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level
JP2003534356A (en) An oil composition comprising short, medium and long chain triglycerides and its use for reducing weight gain.
WO2003056939A1 (en) Oil blends
EP2037757B1 (en) Feed product for dairy cows and method of obtaining a dairy product
Kuipers et al. Milk in the island of Chole [Tanzania] is high in lauric, myristic, arachidonic and docosahexaenoic acids, and low in linoleic acid reconstructed diet of infants born to our ancestors living in tropical coastal regions
JP2525624B2 (en) Baby milk powder containing polyunsaturated fatty acids
US9185922B2 (en) Dairy product
JPS62224258A (en) Nourishing food
Lee Essent ial Fat ty Acids
EP1867242A1 (en) Production method of meat-based products with direct and indirect incorporation of plant and animal fatty substances as carriers of omega-3 and omega-6 fatty acids
JPWO2002094039A1 (en) Foods for improving protein / energy undernutrition
EP1978811B1 (en) Linseed butter and a method of producing linseed butter
JPH02292397A (en) Edible oil or fat composition and processed food
ES2221576B1 (en) BLENDS OF OILS.
WO2018230487A1 (en) Composition and method for suppressing digestive tract symptoms

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141126

RJ01 Rejection of invention patent application after publication